Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia

NICE technology appraisals [TA193] Published date:

NICE recommends taking rituximab, fludarabine and cyclophosphamide together as a possible treatment for some people with relapsed or refractory chronic lymphocytic leukaemia (see below).

Who can have rituximab?

You should be able to have rituximab, fludarabine and cyclophosphamide together unless:

  • you have had rituximab before (see below) or
  • you have had fludarabine before and your condition did not respond to it or worsened within 6 months of treatment.

If you have had rituximab before

If this was part of a research study and one of the following conditions applies, you should still be able to have rituximab, fludarabine and cyclophosphamide together:

  • the dose of rituximab you had was lower than normally used to treat chronic lymphocytic leukaemia or
  • you had rituximab with other chemotherapy instead of fludarabine and cyclophosphamide.

If the conditions described above do not apply, you should only have rituximab again if you are taking part in a research study.

Rituximab with other chemotherapy

If your healthcare professional thinks that rituximab with other chemotherapy instead of fludarabine and cyclophosphamide is appropriate for you, you should only have rituximab if you are taking part in a research study.

Get involved